<DOC>
	<DOCNO>NCT00856336</DOCNO>
	<brief_summary>This phase I study aim identify safe dos DMXAA ( know ASA404 ) use future combination study chemotherapy .</brief_summary>
	<brief_title>Phase I Safety Study DMXAA Refractory Tumors</brief_title>
	<detailed_description>This multi-centre randomized , double blind study characterize effect DMXAA QTc interval , ophthalmic safety pharmacodynamic effect tumour blood flow . Patients refractory tumor undergo six dos treatment weekly interval , receive six dos DMXAA ( 300 , 600 , 1200 , 1800 , 2400 3000 mg/m2 )</detailed_description>
	<mesh_term>Vadimezan</mesh_term>
	<criteria>1 . Evidence cancer , histopathology cytology , amenable standard therapy refractory conventional therapy 2 . Age ≥ 18 year 3 . Life expectancy least 12 week 4. WHO performance status 02 5 . Hematological biochemical index start treatment : 1 . Hemoglobin least 9 g/dl 2 . Leukocyte count least 3.0 x 109/l 3 . Neutrophils least 1.5 x 109/l 4 . Platelets least 100 x 109/l 5 . Serum Creatinine high than140 μmol/l 6 . Liver function test ( ALT , AST , ALK PHOS ) high thrice upper limit reference range , demonstrable liver metastases 5 x upper limit normal range presence liver bone metastases 7 . Absolute QTc interval value less 470 m female less 450 m male assess Investigator 6 . Presence lesion amenable dynamic MRI 7 . Written inform consent ability patient cooperate treatment follow 1 . Radiotherapy ( except palliative reason ) , endocrine therapy , immunotherapy chemotherapy previous four week prior treatment 2 . Pregnant lactate woman exclude 3 . Patients poor medical risk nonmalignant systemic disease , well active uncontrolled infection 4 . Current malignancy sit 5 . Significant history recreational drug abuse 6 . Glucocorticosteroids dose exceed require physiological replacement within previous 2 week 7 . Skin lesion may prevent longterm ECG acquisition 8 . Body mass index 30 kg/m2 9 . Patients take certain medication 10 . Patients clinical evidence brain metastasis 11 . Patients certain cardiac condition 1 . Advancing unstable ischemic heart disease 2 . Pacing device and/or implantable cardiovertordefibrillator 3 . Significant cardiovascular disease unstable cardiovascular disease 4 . Nonsustained sustained atrial and/or ventricular tachyarrhythmias 5 . Atrial fibrillation ( include paroxysmal atrial fibrillation ) atrial flutter 6 . Bundle Branch Block , stable intracardiac conduction abnormality QRS complex &gt; 120 m , unstable intracardiac conduction abnormality 7 . Sick sinus syndrome , sinus pause &gt; 2 second 8 . Known atrial and/or ventricular ectopic beat &gt; 10/hour 9 . Fixed second degree AV block , transient fix third degree AV block 10 . History document ventricular flutter , ventricular fibrillation , Torsade de Pointes tachycardia 11 . Patients previously receive anthracyclines know cardiotoxic medication 12 . Women breast implant may interfere record ECG 13 . Patients severe electrolyte abnormality patient transient electrolyte abnormality may expect visit study 14 . Patients concomitant neurotropic drug therapy know change likely change course study , therapy likely affect patient ERG measurement 15 . Ophthalmic condition opinion investigator might affect record ERG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>